Collectively, these results demonstrate that Bortezomib could indeed elevate ER stress in ErbB2-overexpressing breast cancer cells and that this effect was more pronounced in CHIP-low cells, supporting the rationale to test the effect of this inhibitor against control vs. CHIP KD tumor cells. The gene discussed is ERBB2; the disease is neoplasm.